Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation

Launched by UNIVERSITY OF ALBERTA · Feb 16, 2011

Keywords

ClinConnect Summary

This clinical trial is focused on improving the way doctors diagnose problems in kidney transplants. Currently, doctors use a method called the Banff Classification, which can sometimes lead to incorrect diagnoses and inappropriate treatments. Researchers at the Alberta Transplant Applied Genomics Centre (ATAGC) have developed a new diagnostic system that combines different types of information, including molecular data from the biopsies, to provide a more accurate diagnosis. This trial aims to test and refine this new system using kidney biopsies from up to 1,500 patients across North America and Europe.

To participate in this study, you must be at least 18 years old and a kidney transplant recipient who is undergoing a biopsy for medical reasons. If you choose to join, you can expect to contribute to an important research effort that may lead to better diagnosis and treatment for kidney transplant issues. The study not only seeks to improve diagnostic accuracy but will also create a clear way for doctors to communicate the findings, ensuring that patients receive the best possible care. If you have any questions or concerns about participating, your healthcare team can provide more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All kidney transplant recipients ≥18yrs of age undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enrol in the study.
• Exclusion Criteria:
• • Patients will be excluded from the study if they decline participation or are unable to give informed consent.